2 Responses to “Sedating HIV-Infected Endoscopy Patients”
M. Brian Fennerty, MD
Founding Editor
NEJM Journal Watch Gastroenterology
Learn more about Gut Check on Gastroenterology.
From NEJM: Recently in Gastroenterology- Thrombopoietin-Receptor Agonists in Chemotherapy-Induced Thrombocytopenia March 12, 2026Myelosuppression has long been the major dose-limiting toxic effect of chemotherapy in treating cancer. Reducing the severity of chemotherapy-induced myelosuppression addresses two priorities. One is to prevent myelosuppressive complications — neutropenia and thrombocytopenia, in particular — that can lead to febrile neutropenia, infection, and bleeding. A second priority centers around...
- Helicobacter pylori Screen-and-Treat Programs for Gastric Cancer Prevention — IARC Working Group Report March 12, 2026The IARC Working Group summarizes guidance on H. pylori screen-and-treat programs for gastric cancer prevention and concludes that prevention is the most effective strategy amid a rising global burden.
- Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia March 12, 2026In a phase 3 trial in patients with persistent chemotherapy-induced thrombocytopenia, 84% of those receiving romiplostim had no chemotherapy dose modifications, as compared with 36% of those receiving placebo (odds ratio, 10.16).
- Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma March 5, 2026Neoadjuvant gemcitabine–oxaliplatin, lenvatinib, and anti–PD-1 antibody led to longer event-free survival than surgery alone in resectable high-risk intrahepatic cholangiocarcinoma, with mainly low-grade adverse events.
- The Growing Success of Medicare Drug-Price Negotiation February 26, 2026Medicare will achieve greater savings on the 15 drugs in its second round of price negotiations than it did in the first round. Despite new challenges, the effort should continue to pay growing dividends.
- Thrombopoietin-Receptor Agonists in Chemotherapy-Induced Thrombocytopenia March 12, 2026
Brian, thanks for getting this issue out there to your GI colleagues. We have a meeting with the group in charge of policy on “conscious sedation,” and this specific question will be discussed — hope to get it resolved.
Just for the record, our HIV patients now have a projected life expectancy estimated to be decades — cancer screening recommendations that apply to HIV negative patients apply equally to them. Furthermore, the vast majority of HIV patients on antiviral therapy are receiving either efavirenz or ritonavir, so this issue of sedation for colonoscopies is a highly relevant question.
Propofol